Form 4 for VERA Vera Therapeutics, Inc.
Accepted 2023-02-08 00:00:00 ET · period of report 2023-02-06 · accession 0000899243-23-004345 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-02-08 | 2023-02-06 | VERA | ENRIGHT PATRICK G | Dir, 10% | P - Purchase | $7.00 | +1.71M | 1.71M | New | +$12.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-02-06 | P | A | 1,714,285 | $7.00 | 1,714,285 | I See footnote | — | — | (F1) These shares are held by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting and dispositive power over the shares held by LPF. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |